Ge Long Hui·2026-03-01 22:52Core Viewpoint - China Biologic Products (01177.HK) has received approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug, Rovaxitinib Tablets (brand name: Anxu®), for first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) [1] Group 1 - Rovaxitinib is a globally innovative small molecule inhibitor targeting both JAK and ROCK pathways, providing dual effects of anti-inflammation and anti-fibrosis [1] - The drug works by inhibiting the JAK1/2-STAT3/5 signaling pathway, reducing high levels of inflammatory cytokines produced by myeloid cells, thus improving splenomegaly and systemic symptoms [1] - Additionally, it suppresses ROCK1/2 to lower the polarization level of T helper cells and the burden of inflammatory cytokines in patients with myelofibrosis, further enhancing anti-inflammatory effects and supporting long-term disease control [1]